NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

急性腎障礙 (AKI) - KOL的考察,競爭情報,市場分析、預測 (∼2030年)

Acute Kidney Injury (AKI) | Primary Research (KOL's Insight) | Competitive Intelligence | Market Analytics & Forecast 2030

出版商 Mellalta Meets LLP 商品編碼 997045
出版日期 內容資訊 英文 137 Pages
訂單完成後即時交付
價格
急性腎障礙 (AKI) - KOL的考察,競爭情報,市場分析、預測 (∼2030年) Acute Kidney Injury (AKI) | Primary Research (KOL's Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
出版日期: 2020年11月30日內容資訊: 英文 137 Pages
簡介

2019年的主要市場上急性腎障礙 (AKI) 和確診的病例數,是約195萬人。由於人口動態的變化和急性腎障礙 (AKI)的相關疾病的病例數增加,預計2030年病例數超過208萬人。

AKI的綜合治療市場銷售量,預計至2030年達到52億美元。

急性腎障礙 (AKI)的發病數量

急性腎障礙 (AKI)的市場預測:各國

本報告提供急性腎障礙 (AKI) 市場相關調查分析,市場趨勢,G7病例數,市場機會,市場預測,競爭分析等相關的系統性資訊。

目錄

急性腎障礙 (AKI)的背景

  • 急性腎障礙 (AKI)的定義
  • 症狀
  • 危險因素
  • 診斷

流行病學估計與預測

流行病學的調查手法與使用的資料來源

  • 美國的急性腎障礙 (AKI)的發病數量
  • 美國的相關各疾病的急性腎障礙 (AKI)的病例數
  • 德國的急性腎障礙 (AKI)的發病數量
  • 德國的相關各疾病的急性腎障礙 (AKI)的病例數
  • 法國的急性腎障礙 (AKI)的發病數量
  • 法國的相關各疾病的急性腎障礙 (AKI)的病例數
  • 義大利的急性腎障礙 (AKI)的發病數量
  • 義大利的相關各疾病的急性腎障礙 (AKI)的病例數
  • 西班牙的急性腎障礙 (AKI)的發病數量
  • 西班牙的相關各疾病的急性腎障礙 (AKI)的病例數
  • 英國的急性腎障礙 (AKI)的發病數量
  • 英國的相關各疾病的急性腎障礙 (AKI)的病例數
  • 日本的急性腎障礙 (AKI)的發病數量
  • 日本的相關各疾病的急性腎障礙 (AKI)的病例數

急性腎障礙 (AKI) 的現在未滿足需求

目前治療範例

  • 急性腎障礙 (AKI)的治療指南
  • 急性腎障礙 (AKI) 中RRT的管理

新興治療藥

  • alkaline phosphatase:AM-Pharma
  • ASP 1128:Astellas
  • refanalin:Angion
  • teprasiran:Quark Therapeutics
  • Bovine intestinal alkaline phosphatase:Alloksys
  • reltecimod:AtoxBio
  • EA-230:Exponential Biotherapies
  • conestat alfa:Pharming
  • DUR-928:Durect
  • SBI-10:Sentien Biotechnologies

AKI產品的地位

主要的競爭企業

綜合市場預測

主要摘要的結果

  • G7急性腎障礙 (AKI) 綜合市場
  • G7急性腎障礙 (AKI) 綜合市場:各治療

市場預測:各國

  • 美國
    • 急性腎障礙 (AKI)的美國市場
    • 急性腎障礙 (AKI)的美國市場:各治療
  • 德國
    • 急性腎障礙 (AKI)的德國市場
    • 急性腎障礙 (AKI)的德國市場:各治療
  • 法國
    • 急性腎障礙 (AKI)的法國市場
    • 急性腎障礙 (AKI)的法國市場:各治療
  • 義大利
    • 急性腎障礙 (AKI)的義大利市場
    • 急性腎障礙 (AKI)的義大利市場:各治療
  • 西班牙
    • 急性腎障礙 (AKI)的西班牙市場
    • 急性腎障礙 (AKI)的西班牙市場:各治療
  • 英國
    • 急性腎障礙 (AKI)的英國市場
    • 急性腎障礙 (AKI)的英國市場:各治療
  • 日本
    • 急性腎障礙 (AKI)的日本市場
    • 急性腎障礙 (AKI)的日本市場:各治療

市場促進因素與阻礙

附錄

目錄
Product Code: MM202020

Growth of the incidence AKI population will contribute to increasing sales in the AKI therapy market over our forecast period. An estimated annual growth rate of 2.68% in the diagnosed incident AKI population across the major pharmaceutical markets will contribute to increasing AKI therapy sales. In 2019, there were approximately 1.95 million diagnosed cases of AKI in the major markets; we expect the number of cases will exceed 2.08 million in 2030 owing to changes in population demographics and increasing cases of AKI associated conditions such as sepsis-AKI, Cardiac surgery-associated AKI and others.

The continuous involvement of supportive treatments including renal replacement therapies for the management of AKI patients will contribute to the the overall growth of the AKI therapy market. We forecast that total sales of the total care market will reach $5.2 billion by 2030.

Acute kidney injury - AKI is common in hospitalized adults and children and associated with serious complications and high health care costs. Being hospitalized, especially for a serious condition that requires intensive care, advanced age, blockages in the blood vessels in arms or legs (peripheral artery disease), diabetes, high blood pressure, heart failure, kidney diseases, liver diseases, certain cancers and their treatments are the major causative factors that contributes to the incidence of AKI between different countries.

Acute Kidney Injury -AKI Epidemiology

Mellalta Meets has adopted the findings from a meta-analysis study conducted by International Society of Nephrology's 0by25 initiative for acute kidney injury (Ravindra L Mehta, 2015). In the base year of our study period, we estimate an AKI prevalence of 275 per million people in Japan, 1811 per million in the five European markets covered in this report (France, Germany, Italy, Spain, and the United Kingdom), and 3000-5000 per million in the United States. The reported studies from high-income countries are focused on studies that defines AKI on the basis of the RIFLE, AKIN, and KDIGO diagnostic criteria, because they allow a more accurate ascertainment of the incidence and outcomes of AKI in high-income countries, therefore, we expect 100% diagnosis rate. Therefore. We hold our diagnosed and treatment cases estimates constant over the forecast period, and changes in the number of AKI cases are due to demographic shifts.

AKI Incident Cases -Mellalta meets

Acute Kidney Injury-AKI Market Forecast

The Acute Kidney Injury (AKI) therapy market is expected to experience high growth throughout our study period, increasing from $XX billion in 2019 to $XX billion in 2030, representing 2.6% annual growth. Primary drivers of this growth will be uptake of the novel 6 months treatment i.e. Refanalin (Angion), teprasiran (Quark/Novartis), bRESCAP (Alloksys), recAP (AM Pharma), Conestat alfa (Pharming) and ASP-1128 (Astellas), along with an expanding number of AKI cases associated with sepsis, Cardiac surgery and contrast induced angiography (CIN), CIVID-19 associated AKI and delayed graft function (DGF), predominantly in the United States.

Most interviewed experts believe, that patients will benefit from the upcoming therapies launching in the Sepsis-associated AKI (SA-AKI), Cardiac Surgery associated AKI (CSA-AKI) and others including, delayed graft function and for the prevention of the contrast induced AKI (CA-AKI) in coronary angiography. Refanalin(Angion) will be the first therapy which will be launched in the market for CSA-AKI and will have first mover advantage over other therapies which are launching in same space such as teprasiran (Quark/Novartis), ASP-1128 (Astellas) and bRESCAP (Alloksys). We also believe that the drug will begin facing competition with its peer therapies as physicians' preference for these agents in terms of knowledge of efficacy and safety grows.

Acute Kidney Injury (AKI)-Market Forecast by Country-Mellalta Meets

Report Highlights:

  • Acute Kidney Injury-AKI Current Market Trends
  • Acute Kidney Injury-AKI Current & Forecasted Cases across the G7 Countries
  • Acute Kidney Injury-AKI Market Opportunities And Sales Potential for Agents
  • Acute Kidney Injury-AKI Patient-based Market Forecast to 2030
  • Acute Kidney Injury-AKI Untapped Business Opportunities
  • Acute Kidney Injury-AKI Product Positioning Vis-a-vis Competitors' Products
  • Acute Kidney Injury-AKI KOLs Insight

Table of Contents

Acute Kidney Injury Disease Background

  • Acute Kidney Injury Definition
  • Symptoms
  • Risk Factor
  • Diagnosis

Epidemiology Estimated and Forecast to 2030

Epidemiology Research Method & Data Sources Used

  • Incident Cases of Acute Kidney Injury in the United States 2020-2030
  • Cases of Acute Kidney Injury by AKI-Associated Conditions in the United States 2020-2030
  • Incident Cases of Acute Kidney Injury in Germany 2020-2030
  • Cases of Acute Kidney Injury by AKI-Associated Conditions in Germany 2020-2030
  • Incident Cases of Acute Kidney Injury in France 2020-2030
  • Cases of Acute Kidney Injury by AKI-Associated Conditions in France 2020-2030
  • Incident Cases of Acute Kidney Injury in Italy 2020-2030
  • Cases of Acute Kidney Injury by AKI-Associated Conditions in Italy 2020-2030
  • Incident Cases of Acute Kidney Injury in Spain 2020-2030
  • Cases of Acute Kidney Injury by AKI-Associated Conditions in Spain 2020-2030
  • Incident of Acute Kidney Injury in the United Kingdom 2020-2030
  • Cases of Acute Kidney Injury by AKI-Associated Conditions in the United Kingdom 2020-2030
  • Incident Cases of Acute Kidney Injury in Japan 2020-2030
  • Cases of Acute Kidney Injury by AKI-Associated Conditions in Japan 2020-2030

Current Unmet Needs in Acute Kidney Injury

Current Treatment Paradigm

  • Treatment guidelines for Acute Kidney Injury
  • Management of RRT in Acute Kidney Injury

Emerging Therapies Chapters

  • alkaline phosphatase, AM-Pharma
  • ASP 1128, Astellas
  • refanalin, Angion
  • teprasiran, Quark Therapeutics
  • Bovine intestinal alkaline phosphatase, Alloksys
  • reltecimod, AtoxBio
  • EA-230, Exponential Biotherapies
  • conestat alfa, Pharming
  • DUR-928, Durect
  • SBI-10, Sentien Biotechnologies

AKI Product Positioning

Key Competitors

Matrix Modeling

Total Market Forecast

Key Summary Findings

  • G7 total Market for Acute Kidney Injury 2020-2030 (USD Million)
  • G7 total Market for Acute Kidney Injury by Therapies 2020-2030 (USD Million)

Market Forecast by Country

  • United States
    • United States Market for Acute Kidney Injury 2020-2030 (USD Million)
    • United States Market for Acute Kidney Injury by Therapies 2020-2030 (USD Million)
  • Germany
    • Germany Market for Acute Kidney Injury 2020-2030 (USD Million)
    • Germany Market for Acute Kidney Injury by Therapies 2020-2030 (USD Million)
  • France
    • France Market for Acute Kidney Injury 2020-2030 (USD Million)
    • France Market for Acute Kidney Injury by Therapies 2020-2030 (USD Million)
  • Italy
    • Italy Market for Acute Kidney Injury 2020-2030 (USD Million)
    • Italy Market for Acute Kidney Injury by Therapies 2020-2030 (USD Million)
  • Spain
    • Spain Market for Acute Kidney Injury 2020-2030 (USD Million)
    • Spain Market for Acute Kidney Injury by Therapies 2020-2030 (USD Million)
  • United Kingdom
    • United Kingdom Market for Acute Kidney Injury 2020-2030 (USD Million)
    • United Kingdom Market for Acute Kidney Injury by Therapies 2020-2030 (USD Million)
  • Japan
    • Japan Market for Acute Kidney Injury 2020-2030 (USD Million)
    • Japan Market for Acute Kidney Injury by Therapies 2020-2030 (USD Million)

Market Drivers & Barriers

Appendix